Conformational states of the corticotropin releasing factor 1 (CRF 1) receptor: Detection, and pharmacological evaluation by peptide ligands

Peptides

Volumn 24, Issue 12, 2003, Pages 1881-1897

  Hoare, Sam R J ^a   Sullivan, Susan K ^a   Pahuja, Anil ^a   Ling, Nicholas ^a   Crowe, Paul D ^a   Grigoriadis, Dimitri E ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Agonist; Corticotrophin releasing factor; G protein coupled receptor; Guanine nucleotide; Ligand binding; Sauvagine; Urocortin

Indexed keywords

ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LIGAND; PEPTIDE; SAUVAGINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CEREBELLUM; CONFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL DETECTION;

EID: 0842265891     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2003.09.002     Document Type: Article

References (50)

1. Brauns O., Brauns S., Zimmerman B., Jahn O., Spiess J. Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands. Peptides. 23:2002;881-888.
2. Chang C.P., Pearse R.V.D., O'Connell S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 11:1993;1187-1195.
3. Chen C., Dagnino R. Jr., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I.et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J. Med. Chem. 39:1996;4358-4360.
4. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. USA. 90:1993;8967-8971.
5. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
6. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125:1998;924-947.
7. Dautzenberg F.M., Py-Lang G., Higelin J., Fischer C., Wright M.B., Huber G. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J. Pharmacol. Exp. Ther. 296:2001;113-120.
8. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255:1980;7108-7117.
9. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 7:1987;88-100.
10. Gilligan P.J., Robertson D.W., Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 43:2000;1641-1660.
11. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu Rev. Biochem. 56:1987;615-649.
12. 3H ]-urocortin Neuropharmacology. 36:1997;1439-1446.
13. Grigoriadis D, Liaw CW, Oltersdorf T, DeSouza EB. Pharmacological characterization of rat and human corticotropin-releasing factor (CRF) receptors expressed in stable cell lines. Society for neuroscience. Miami, FL; 1994.
14. Grigoriadis D.E., De Souza E.B. Corticotropin-releasing factor (CRF) receptors in intermediate lobe of the pituitary: biochemical characterization and autoradiographic localization. Peptides. 10:1989;179-188.
15. Grigoriadis DE, DeSouza EB. Molecular and biochemical characterization of corticotropin releasing hormone (CRH) receptors in brain and periphery. In: Kvetnansky R, McCarty R, Axelrod J, editors. Stress: neuroendocrine and molecular approaches. New York: Gordon and Breach Science 1992. p. 685-703.
16. Grigoriadis D.E., Haddach M., Ling N., Saunders J. The CRF receptor: structure, function and potential for therapeutic intervention. Curr. Med. Chem.-Central Nervous Syst. Agents. 1:2001;63-97.
17. Grigoriadis D.E., Pearsall D., De Souza E.B. Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. Neuropsychopharmacology. 2:1989;53-60.
18. Grigoriadis D.E., Struble R.G., Price D.L., De Souza E.B. Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in Alzheimer's disease: evidence from chemical cross-linking studies. Neuropharmacology. 28:1989;761-764.
19. Grigoriadis D.E., Zaczek R., Pearsall D.M., De Souza E.B. Solubilization of high affinity corticotropin-releasing factor receptors from rat brain: characterization of an active digitonin-solubilized receptor complex. Endocrinology. 125:1989;3068-3077.
20. Gurevich V.V., Pals-Rylaarsdam R., Benovic J.L., Hosey M.M., Onorato J.J. Agonist-receptor-arrestin an alternative ternary complex with high agonist affinity. J. Biol. Chem. 272:1997;28849-28852.
21. Hoare S.R., Gardella T.J., Usdin T.B. Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J. Biol. Chem. 276:2001;7741-7753.
22. Hoare S.R., Sullivan S.K., Ling N., Crowe P.D., Grigoriadis D.E. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol. 63:2003;751-765.
23. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33:1999;181-214.
24. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7:2001;605-611.
25. Kenakin T. Radioligand-binding experiments. Pharmacologic analysis of drug-receptor interaction. Philadelphia: Lippencott-Raven Publishers; 1997. p. 255-8.
26. Key T.A., Bennett T.A., Foutz T.D., Gurevich V.V., Sklar L.A., Prossnitz E.R. Regulation of formyl peptide receptor agonist affinity by reconstitution with arrestins and heterotrimeric G proteins. J. Biol. Chem. 276:2001;49204-49212.
27. Lee T.W., Sole M.J., Wells J.W. Assessment of a ternary model for the binding of agonists to neurohumoral receptors. Biochemistry. 25:1986;7009-7020.
28. Lefkowitz R.J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14:1993;303-307.
29. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C.et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;7570-7575.
30. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain [published erratum appears in Proc Natl Acad Sci USA 1995;692(12):5759]. Proc Natl Acad Sci USA 1995;92:836-40.
31. Martini L., Hastrup H., Holst B., Fraile-Ramos A., Marsh M., Schwartz T.W. NK1 receptor fused to beta-arrestin displays a single-component, high-affinity molecular phenotype. Mol. Pharmacol. 62:2002;30-37.
32. Miranda A., Koerber S.C., Gulyas J., Lahrichi S.L., Craig A.G., Corrigan A.et al. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. J. Med. Chem. 37:1994;1450-1459.
33. Montecucchi P.C., Henschen A. Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of Phyllomedusa sauvagei. Int. J. Pept. Protein Res. 18:1981;113-120.
34. Olianas M.C., Onali P. G protein-coupled corticotropin-releasing hormone receptors in rat retina. Regul. Pept. 56:1995;61-70.
35. Perrin M.H., Donaldson C.J., Chen R., Lewis K.A., Vale W.W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology. 133:1993;3058-3061.
36. Perrin M.H., Haas Y., Rivier J.E., Vale W.W. Corticotropin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides. Endocrinology. 118:1986;1171-1179.
37. Perrin M.H., Sutton S.W., Cervini L.A., Rivier J.E., Vale W.W. Comparison of an agonist, urocortin and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J. Pharmacol. Exp. Ther. 288:1999;729-734.
38. Post S.R., Rubinstein P.G., Tager H.S. Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system. Proc. Natl. Acad. Sci. USA. 90:1993;1662-1666.
39. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A.et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. USA. 98:2001;2843-2848.
40. Rivier C., Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor catecholamines and vasopressin. Nature. 305:1983;325-327.
41. Rivier J., Gulyas J., Kirby D., Low W., Perrin M.H., Kunitake K.et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J. Med. Chem. 45:2002;4737-4747.
42. Rivier J., Rivier C., Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science. 224:1984;889-891.
43. Ruhmann A., Bonk I., Kopke A.K. High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1. Peptides. 20:1999;1311-1319.
44. Ruhmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc. Natl. Acad. Sci. USA. 95:1998;15264-15269.
45. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
46. Van Rampelbergh J., Gourlet P., De Neef P., Robberecht P., Waelbroeck M. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states. Mol. Pharmacol. 50:1996;1596-1604.
47. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S.et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.
48. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M.et al. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett. 335:1993;1-5.
49. Webster E.L., De Souza E.B. Corticotropin-releasing factor receptors in mouse spleen: identification, autoradiographic localization, and regulation by divalent cations and guanine nucleotides. Endocrinology. 122:1988;609-617.
50. Xiong Y., Xie L.Y., Abou-Samra A.B. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology. 136:1995;1828-1834.